Diabetic Dyslipidemia: A Precision Framework for Risk-Based Lipid Management
SMART-MD Journal of Precision Medicine · 31.05.2026 · 3 (2) · e249-e256
DOI: 10.69734/0xp63t08 ↗Kurz gefasst
Fachartikel in der Zeitschrift SMART-MD Journal of Precision Medicine, online erschienen am 31.05.2026. Verfasst von Ali O Balkan MD und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atherogenic dyslipidemia refers to a specific pattern of blood lipid abnormalities that promotes atherosclerotic cardiovascular disease (ASCVD). It is defined by elevated triglycerides (TG ≥150 mg/dL), reduced high-density lipoprotein cholesterol (HDL-C
Zitieren
APA
MD, A. O. B., & MD, E. E. K. (2026). Diabetic Dyslipidemia: A Precision Framework for Risk-Based Lipid Management. SMART-MD Journal of Precision Medicine, 3(2), e249-e256. https://doi.org/10.69734/0xp63t08
Vancouver
MD AOB, MD EEK. Diabetic Dyslipidemia: A Precision Framework for Risk-Based Lipid Management. SMART-MD Journal of Precision Medicine. 2026;3(2):e249-e256. doi:10.69734/0xp63t08
BibTeX
@article{MD2026,
author = {MD, Ali O Balkan and MD, Erin E Kershaw},
title = {Diabetic Dyslipidemia: A Precision Framework for Risk-Based Lipid Management},
journal = {SMART-MD Journal of Precision Medicine},
year = {2026},
volume = {3},
number = {2},
pages = {e249--e256},
doi = {10.69734/0xp63t08}
}
EUVIMED